Alexanian R, Barlogie B, Dixon D
M. D. Anderson Hospital and Tumor Institute, Houston, TX 77030.
Arch Intern Med. 1988 Sep;148(9):1963-5.
Prognostic factors were assessed in 35 consecutive, asymptomatic patients with multiple myeloma. The presence of any lytic bone lesion or a serum myeloma protein concentration of at least 3.0 g/dL was followed by early disease progression and the need for chemotherapy within two years. Such patients require frequent monitoring of electrophoretic data. In patients without these features, the myeloma did not progress for a median of three years and the subsequent median survival time was seven years, identifying those likely to live for ten years after diagnosis. Because the treatment of myeloma remains palliative, chemotherapy should be withheld until symptoms develop or complications are imminent.
对35例连续的无症状多发性骨髓瘤患者的预后因素进行了评估。存在任何溶骨性骨病变或血清骨髓瘤蛋白浓度至少为3.0 g/dL的患者，疾病会早期进展，且在两年内需要化疗。这类患者需要频繁监测电泳数据。在没有这些特征的患者中，骨髓瘤的中位无进展时间为三年，随后的中位生存时间为七年，可据此识别出那些诊断后可能存活十年的患者。由于骨髓瘤的治疗仍为姑息性治疗，因此在症状出现或即将出现并发症之前应暂缓化疗。
